National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dalbavancin (Xydalba®) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults1.

Rapid Review

Commenced Completed Outcome
07/03/2017 28/04/2017 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price